ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I

Biochemistry

Volumn 49, Issue 3, 2010, Pages 532-538

  Gaidukov, Leonid ^a   Viji, R I ^a   Yacobson, Shiri ^a   Rosenblat, Mira ^b   Aviram, Michael ^b   Tawfik, Dan S ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A-I (APOA-I); APOLIPOPROTEINS; ATHEROGENIC POTENTIAL; CHOLESTEROL EFFLUX; ENZYMATIC ACTIVITIES; ENZYME STABILITY; FUNCTIONAL SIMILARITY; HIGH AFFINITY; HIGH-DENSITY LIPOPROTEINS; ISOFORMS; LACTONASE; LACTONASE ACTIVITY; LDL OXIDATION; NANOMOLAR AFFINITY; PROTEIN-PROTEIN INTERACTIONS; SEQUENCE HOMOLOGY;

BODY FLUIDS; ENZYMES; SURFACE PROPERTIES;

ENZYME ACTIVITY;

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ARYLDIALKYLPHOSPHATASE 1; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; ISOENZYME;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME STABILITY; LIPID OXIDATION; MACROPHAGE; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY; SURFACE PROPERTY;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; BINDING SITES; CATALYSIS; ENZYME STABILITY; HUMANS; KINETICS; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; PROTEIN STABILITY; RECOMBINANT PROTEINS;

EID: 74949106771     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi9013227     Document Type: Article

References (61)

1. Mackness, M. I., Mackness, B., Durrington, P. N., Connelly, P. W., and Hegele, R. A. (1996) Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7, 69-76.
2. Reddy, S. T., Wadleigh, D. J., Grijalva, V., Ng, C., Hama, S., Gangopadhyay, A., Shih, D. M., Lusis, A. J., Navab, M., and Fogelman,A.M. (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21, 542-547.
3. Blatter, M. C., James, R. W., Messmer, S., Barja, F., and Pometta, D. (1993) Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211, 871-879.
4. Kelso, G. J., Stuart, W. D., Richter, R. J., Furlong, C. E., Jordan-Starck, T. C., and Harmony, J. A. (1994) Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33, 832-839.
5. Moren, X., Deakin, S., Liu, M. L., Taskinen, M. R., and James, R. W. (2008) HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J. Lipid Res. 49, 1246-1253.
6. Ng, C. J., Shih, D. M., Hama, S. Y., Villa, N., Navab, M., and Reddy, S. T. (2005) The paraoxonase gene family and atherosclerosis. Free Radical Biol. Med. 38, 153-163.
7. Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M., and Mackness, M. (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107, 2775-2779.
8. Cabana, V. G., Reardon, C. A., Feng, N., Neath, S., Lukens, J., and Getz, G. S. (2003) Serum paraoxonase: Effect of the apolipoprotein composition of HDL and the acute phase response. J. Lipid Res. 44, 780-792.
9. Draganov, D. I., Teiber, J. F., Speelman, A., Osawa, Y., Sunahara, R., and La Du, B. N. (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46, 1239-1247.
10. Khersonsky, O., and Tawfik, D. S. (2005) Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44, 6371-6382.
11. Rosenblat, M., Gaidukov, L., Khersonsky, O., Vaya, J., Oren, R., Tawfik, D. S., and Aviram, M. (2006) The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281, 7657-7665.
12. Khersonsky, O., and Tawfik, D. S. (2006) The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem. 281, 7649-7656.
13. Gaidukov, L., and Tawfik, D. S. (2005) High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44, 11843-11854.
14. Lund-Katz, S., Liu, L., Thuahnai, S. T., and Phillips, M. C. (2003) High density lipoprotein structure. Front. Biosci. 8, d1044-d1054.
15. Kontush, A., and Chapman, M. J. (2006) Functionally defective highdensity lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58, 342-374.
16. Krimbou, L., Marcil, M., Chiba, H., and Genest, J., Jr. (2003) Structural and functional properties of human plasma high densitysized lipoprotein containing only apoE particles. J. Lipid Res. 44, 884-892.
17. Asztalos, B. F., Horvath, K. V., Kajinami, K., Nartsupha, C., Cox, C. E., Batista, M., Schaefer, E. J., Inazu, A., and Mabuchi, H. (2004) Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J. Lipid Res. 45, 448-455.
18. Rall, S. C., Jr., Weisgraber, K. H., and Mahley, R. W. (1982) Human apolipoprotein E. The complete amino acid sequence. J. Biol. Chem. 257, 4171-4178.
19. Weisgraber, K. H., Rall, S. C., Jr., and Mahley, R. W. (1981) Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 256, 9077-9083.
20. Weisgraber, K. H. (1990) Apolipoprotein E distribution among human plasma lipoproteins: Role of the cysteine-arginine interchange at residue 112. J. Lipid Res. 31, 1503-1511.
21. Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setala, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., and Breslow, J. L. (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343-353.
22. Schaefer, E. J., Gregg, R. E., Ghiselli, G., Forte, T. M., Ordovas, J. M., Zech, L. A., and Brewer, H. B., Jr. (1986) Familial apolipoprotein E deficiency. J. Clin. Invest. 78, 1206-1219.
23. Kypreos, K. E., and Zannis, V. I. (2006) LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J. Lipid Res. 47, 521-529.
24. Thorngate, F. E., Rudel, L. L., Walzem, R. L., and Williams, D. L. (2000) Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20, 1939-1945.
25. Tsukamoto, K., Tangirala, R., Chun, S. H., Pure, E., and Rader, D. J. (1999) Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19, 2162-2170.
26. Raffai, R. L., Loeb, S. M., and Weisgraber, K. H. (2005) Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 25, 436-441.
27. Remaley, A. T., Stonik, J. A., Demosky, S. J., Neufeld, E. B., Bocharov, A. V., Vishnyakova, T. G., Eggerman, T. L., Patterson, A. P., Duverger, N. J., Santamarina-Fojo, S., and Brewer, H. B., Jr. (2001) Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem. Biophys. Res. Commun. 280, 818-823.
28. Tsukamoto, K., Tangirala, R. K., Chun, S., Usher, D., Pure, E., and Rader, D. J. (2000) Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. Mol. Ther. 1, 189-194.
29. Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., and Danesh, J. (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA, J. Am. Med. Assoc. 298, 1300-1311.
30. Ryan, R. O., Forte, T. M., and Oda, M. N. (2003) Optimized bacterial expression of human apolipoprotein A-I. Protein Expression Purif. 27, 98-103.
31. Li, X., Kypreos, K., Zanni, E. E., and Zannis, V. (2003) Domains of apoE required for binding to apoE receptor 2 and to phospholipids: Implications for the functions of apoE in the brain. Biochemistry 42, 10406-10417.
32. Morrow, J. A., Arnold, K. S., and Weisgraber, K. H. (1999) Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. Protein Expression Purif. 16, 224-230.
33. Gaidukov, L., Rosenblat, M., Aviram, M., and Tawfik, D. S. (2006) The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J. Lipid Res. 47, 2492-2502.
34. Aviram, M. (1983) Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem. Med. 30, 111-118.
35. Buege, J. A., and Aust, S. D. (1978) Microsomal lipid peroxidation. Methods Enzymol. 52, 302-310.
36. Aharoni, A., Gaidukov, L., Yagur, S., Toker, L., Silman, I., and Tawfik, D. S. (2004) Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. U.S.A. 101, 482-487.
37. Krimbou, L., Denis, M., Haidar, B., Carrier, M., Marcil, M., and Genest, J., Jr. (2004) Molecular interactions between apoE and ABCA1: Impact on apoE lipidation. J. Lipid Res. 45, 839-848.
38. Durrington, P. N., Mackness, B., and Mackness, M. I. (2001) Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 473-480.
39. Costa, L. G., Cole, T. B., Jarvik, G. P., and Furlong, C. E. (2003) Functional genomic of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu. Rev. Med. 54, 371-392.
40. Shih, D. M., Gu, L., Xia, Y. R., Navab, M., Li, W. F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M., and Lusis, A. J. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-287.
41. Lusis, A. J. (2000) Atherosclerosis. Nature 407, 233-241.
42. Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., and Rosenblat, M. (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101, 2510-2517.
43. Navab, M., Ananthramaiah, G. M., Reddy, S. T., Van Lenten, B. J., Ansell, B. J., Fonarow, G. C., Vahabzadeh, K., Hama, S., Hough, G., Kamranpour, N., Berliner, J. A., Lusis, A. J., and Fogelman, A. M. (2004) The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J. Lipid Res. 45, 993-1007.
44. Lagrost, L., Dengremont, C., Athias, A., de Geitere, C., Fruchart, J. C., Lallemant, C., Gambert, P., and Castro, G. (1995) Modulation of cholesterol efflux from Fu5AH hepatoma cells by the apolipoprotein content of high density lipoprotein particles. Particles containing various proportions of apolipoproteins A-I and A-II. J. Biol. Chem. 270, 13004-13009.
45. Mahley, R. W., and Rall, S. C., Jr. (2000) Apolipoprotein E: Far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1, 507-537.
46. Hatters, D. M., Peters-Libeu, C. A., and Weisgraber, K. H. (2006) Apolipoprotein E structure: Insights into function. Trends Biochem. Sci. 31, 445-454.
47. Mahley, R. W., and Ji, Z. S. (1999) Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40, 1-16.
48. Nguyen, D., Dhanasekaran, P., Phillips, M. C., and Lund-Katz, S. (2009) Molecular mechanism of apolipoprotein E binding to lipoprotein particles. Biochemistry 48, 3025-3032.
49. Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R. B., McCarthy, A., Toker, L., Silman, I., Sussman, J. L., and Tawfik, D. S. (2004) Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat. Struct. Mol. Biol. 11, 412-419.
50. Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G., and James, R. W. (2002) Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277, 4301-4308.
51. Li, W. H., Tanimura, M., Luo, C. C., Datta, S., and Chan, L. (1988) The apolipoprotein multigene family: Biosynthesis, structure, structure-function relationships, and evolution. J. Lipid Res. 29, 245-271.
52. Saito, H., Lund-Katz, S., and Phillips, M. C. (2004) Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog. Lipid Res. 43, 350-380.
53. Segrest, J. P., Jones, M. K., Klon, A. E., Sheldahl, C. J., Hellinger, M., De Loof, H., and Harvey, S. C. (1999)Adetailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J. Biol. Chem. 274, 31755-31758.
54. Narayanaswami, V., Maiorano, J. N., Dhanasekaran, P., Ryan, R.O., Phillips, M. C., Lund-Katz, S., and Davidson,W. S. (2004)Helix orientation of the functional domains in apolipoprotein E in discoidal high density lipoprotein particles. J. Biol. Chem. 279, 14273-14279.
55. Wu, Z., Wagner, M. A., Zheng, L., Parks, J. S., Shy, J. M., III, Smith, J. D., Gogonea, V., and Hazen, S. L. (2007) The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 14, 861-868.
56. Tubb, M. R., Silva, R. A., Fang, J., Tso, P., and Davidson, W. S. (2008) A three-dimensional homology model of lipid-free apolipoprotein A-IV using cross-linking and mass spectrometry. J. Biol. Chem. 283, 17314-17323.
57. Wong, W. M., Gerry, A. B., Putt, W., Roberts, J. L., Weinberg, R. B., Humphries, S. E., Leake, D. S., and Talmud, P. J. (2007) Common variants of apolipoprotein A-IV differ in their ability to inhibit low density lipoprotein oxidation. Atherosclerosis 192, 266-274.
58. Plump, A. S., Azrolan, N., Odaka, H., Wu, L., Jiang, X., Tall, A., Eisenberg, S., and Breslow, J. L. (1997) ApoA-I knockout mice: Characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J. Lipid Res. 38, 1033-1047.
59. Deakin, S., Moren, X., and James, R. W. (2005) Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 179, 17-25.
60. Boucher, J., Ramsamy, T. A., Braschi, S., Sahoo, D., Neville, T. A., and Sparks, D. L. (2004) Apolipoprotein A-II regulates HDL stability and affects hepatic lipase association and activity. J. Lipid Res. 45, 849-858.
61. Navab, M., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J., Datta, G., Garber, D., and Fogelman, A.M. (2006) Potential clinical utility of high-density lipoprotein-mimetic peptides. Curr. Opin. Lipidol. 17, 440-444.